Aurobindo Pharma Share Price
Mid Cap | Pharmaceuticals and health care | NSE: AUROPHARMA | BSE: 524804
₹1,110.00 
-10.85 (-0.97 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 1,121.30
High (₹) 1,125.55
Low (₹) 1,097.75
Prev. Close (₹) 1,120.85
Volume 39,011
VWAP (₹) 1,110.95
ROCE (%) 14.84
Industry P/E 43.99
TTM P/E 18.47
P/B Ratio 2.19
Market Cap (₹) Cr.64,768.09
Dividend Yield (%)0.41
EPS (₹) 54.16
ROE10.63%
Sales Growth (%) 16.68
Profit Growth (%)64.29
Day Range
1,125.551,125.55
52 Week Range
985.001,592.55
Historical Returns
Returns (6M)
-28.31 %
Returns (1Y)
6.29 %
Returns (3Y)
74.62 %
Returns (5Y)
120.3 %
Returns (6M)
-28.31 %
Returns (1Y)
6.29 %
Returns (3Y)
74.62 %
Returns (5Y)
120.3 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Company with (64.62%) TTM EPS Growth
- Company with Low Debt
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Company with 64.62% positive TTM EPS growth
- Increasing Annual Revenue for Past 2 Years
- Bullish MACD crossover (12,6,9) indicates potential upward price movement.
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
BEARISHRSI 62.46
MFI 48.87
ATR 47.63
Commodity Channel Index -143.79
ROC125 -27.48
ROC21 -7.95
Williams %R -62.57
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 1,128.09 | 1,140.72 | 1,155.89 | 1,112.92 | 1,100.29 | 1,085.12 | 1,072.49 |
| Week Ago | 1,176.69 | 1,223.57 | 1,250.59 | 1,149.67 | 1,102.79 | 1,075.77 | 1,028.89 |
| Month Ago | 1,209.09 | 1,231.47 | 1,243.69 | 1,196.87 | 1,174.49 | 1,162.27 | 1,139.89 |
EMA & SMA
1110.00
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 1150.91
9 Day 1145.67
10 Day 1153.68
12 Day 1163.26
14 Day 1160.97
20 Day 1155.64
26 Day 1170.40
50 Day 1208.17
100 Day 1286.71
200 Day 1320.81
Deals & Announcements
Bulk and Block Deals
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BNP PARIBAS ARBITRAGE | block | Sell | 25 Jan, 2024 | ₹1,160.10 | 14,84,323 | BSE |
| SOCIETE GENERALE | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 14,84,323 | BSE |
| MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 27,571 | BSE |
| MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 15,950 | BSE |
| MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND | block | Buy | 25 Jan, 2024 | ₹1,160.10 | 1,06,480 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 25 Oct, 2022 | ₹524.50 | 2,77,213 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 25 Oct, 2022 | ₹524.50 | 2,77,213 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 17 Oct, 2022 | ₹514.05 | 4,35,602 | BSE |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 17 Oct, 2022 | ₹514.05 | 4,35,602 | BSE |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 11 Oct, 2022 | ₹535.45 | 3,19,465 | BSE |
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 01 Apr, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,088.750000042970602435814381 | 1,16,35,862 | BSE |
| 28 Mar, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Pledge | ₹1,053.05 | 1,67,00,000 | BSE |
| 25 Mar, 2024 | A.Janardhana Kamath | Disposal | ₹1,013.492666666666666666666667 | 6,000 | BSE |
| 05 Mar, 2024 | Pavankumar PS | Disposal | ₹1,022.00 | 1,000 | BSE |
| 01 Mar, 2024 | Chandrasekhar Reddy Kandati | Disposal | ₹1,047.3875 | 2,000 | BSE |
| 26 Feb, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,043.80 | 23,00,000 | BSE |
| 26 Feb, 2024 | RPR Sons Advisors Pvt.Ltd. Mrs.P.Suneela Rani jointly holding | Revoke | ₹1,043.80 | 1,00,50,000 | BSE |
| 23 Feb, 2024 | Pavankumar PS | Disposal | ₹1,025.00 | 1,000 | BSE |
| 21 Feb, 2024 | Ambati Rama Mohan Rao | Disposal | ₹1,020.00 | 5,000 | BSE |
| 21 Feb, 2024 | K.Nagaraju | Disposal | ₹1,048.46 | 5,000 | BSE |
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 07 Feb, 2024 | Rs.1.5000 per share(150%)Second Interim Dividend | 20 Feb, 2024 | 20 Feb, 2024 |
| 02 Nov, 2023 | Rs.3.0000 per share(300%)First Interim Dividend | 20 Nov, 2023 | 20 Nov, 2023 |
| 03 Feb, 2023 | Rs.3.0000 per share(300%)Interim Dividend | 17 Feb, 2023 | 17 Feb, 2023 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 20 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Schedule of meet |
| 20 Feb, 2025 | BSE India | Intimation of Investor Group Plant visit arranged by B&K Securities |
| 20 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange regarding ''Classification of US FDA Inspection at one of the warehouses of Aurobindo Pharma USA Inc., a 100% subsidiary of the Company. Reg.,''. |
| 19 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Schedule of meet |
| 19 Feb, 2025 | BSE India | Intimation of Investor Meet on February 25, 2025 |
| 18 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange regarding ''Completion of US FDA Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company''. |
| 18 Feb, 2025 | BSE India | Intimation of completion of USFDA pre-approval (PAI) of Eugia Steriles Private Limited, a 100% stepdown subsidiary of the Company. |
| 18 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Schedule of meet |
| 18 Feb, 2025 | BSE India | Intimation of Plant Visit by investor Group at Jadcherla Plant on February 21, 2025 |
| 17 Feb, 2025 | NSE India | Aurobindo Pharma Limited has informed the Exchange about Schedule of meet |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 20 Jan, 2025 | 06 Feb, 2025 |
| Quarterly Results | -- | 05 Nov, 2024 | 09 Nov, 2024 |
| Quarterly Results | -- | 01 Aug, 2024 | 10 Aug, 2024 |
| Buy Back of Shares | To consider buyback for equity shares | 18 Jul, 2024 | 18 Jul, 2024 |
| Audited Results | -- | 30 May, 2024 | 25 May, 2024 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 10 Feb, 2024 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 09 Nov, 2023 |
| Quarterly Results | -- | 30 May, 2024 | 12 Aug, 2023 |
| Audited Results | -- | 30 May, 2024 | 27 May, 2023 |
| Quarterly Results & Interim Dividend | -- | 30 May, 2024 | 09 Feb, 2023 |
Share Holding Pattern
| Owner Name | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 | Sept, 2023 |
|---|
About Aurobindo Pharma
Aurobindo Pharma is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 10645.64 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1986
Managing Director
-- --
NSE Symbol
AUROPHARMA
Aurobindo Pharma Management
| Name | Designation |
|---|---|
| Mr. M Ramasubramanian Kumar | Chairman & Ind.Dire (Non-Exe) |
| Mr. K Nithyananda Reddy | Vice Chairman & Mng.Director |
| Mr. M Madan Mohan Reddy | Whole Time Director |
| Mr. P V Ramprasad Reddy | Non Executive Director |
| Dr. Satakarni Makkapati | Non Executive Director |
| Mr. P Sarath Chandra Reddy | Non Executive Director |
| Mr. Girish P Vanvari | Independent Director |
| Mrs. Savita Mahajan | Independent Director |
| Mr. Santanu Mukherjee | Independent Director |
| Dr. Deepali Pant Joshi | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Aurobindo Pharma
What is the share price of Aurobindo Pharma?
The share price of Aurobindo Pharma on 21 Feb, 2025 is ₹ 1,110.00.
What is 52W high and 52W low share price of Aurobindo Pharma?
The highest and lowest 52W share prices of Aurobindo Pharma are ₹ 1592.550 and ₹ 959.050
What is the market cap of Aurobindo Pharma?
The market capitalization of Aurobindo Pharma as of 21 Feb, 2025 is ₹ 64,768.09 Crores
What is the P/E ratio of Aurobindo Pharma?
The current P/E ratio of Aurobindo Pharma as of 21 Feb, 2025 is 43.99
What is the PB ratio of Aurobindo Pharma?
The PB ratio of Aurobindo Pharma as of 21 Feb, 2025 is 2.19
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)